QuickView for complement component C5a receptor activity (biogroup)

1. Bone marrow derived macrophage gene expression upon infection with Anaplasma phagocytophilum
2. Microglia from cerebral cortex of FOSB null mutants
3. PBMCs from hematological malignancies treated with cyclophosphamide
4. Monocytes from peripheral blood of young and old donors treated with RIG-I ligand
5. Dendritic cell subpopulations' expression profiles

There were no matches for complement component C5a receptor activity

1. First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects
2. Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects.
3. A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
4. NETs: Protection or Harm in Neonatal Inflammation or Infection
5. Convalescent Antibodies Infusion in COVID 19 Patients